The company’s initial commercial programs in mainland China expand its geographic reach and mark a new step in the global rollout of its human tissue-based drug testing platform.
Key Investor Takeaways
- VivoSim (NASDAQ:VIVS) secured its first commercial sales in mainland China through two paid customer engagements.
- The VivoSim China commercial sales expand the company’s NAMkind™ toxicology and efficacy testing platform into one of the world’s largest pharmaceutical markets.
- The initial contracts cover gastrointestinal toxicology screening and efficacy profiling for drug candidates in oncology and other disease areas.
- Management said the two engagements represent a meaningful portion of the company’s contracted revenue to date.
- Investors will be watching whether these initial programs lead to additional commercial customers and broader adoption across the Asia-Pacific region.
Why VIVS Stock Is in Focus
VivoSim announced its first commercial sales in mainland China through two paid testing programs secured by its local distributor, Tekon. The engagements involve a Shanghai-based oncology biotechnology company and a pharmaceutical company headquartered in Chengdu.
The projects cover gastrointestinal toxicology screening and NAMkind™ gastrointestinal efficacy testing for candidate therapies and represent VivoSim’s first paid commercial work in China. According to the company, the contracts account for a meaningful share of its contracted revenue to date and establish a commercial presence in the Chinese market.
Management estimates the addressable Chinese market for liver and gastrointestinal in vitro models and toxicology services at approximately $2 billion, with projected annual growth of around 10%. VivoSim said increasing regulatory acceptance of scientifically validated non-animal testing approaches could support wider adoption of its human tissue-based models.
“China is now the world’s second-largest pharmaceutical market and among the fastest-moving sources of drug innovation globally, and these first two sales show there is real, paying demand for the human-relevant safety and efficacy data VivoSim is built to deliver,” said Tony Lialin, Chief Commercial Officer of VivoSim. “Landing our first paid programs on the mainland validates our channel strategy and gives us a beachhead to scale a market we believe can become a meaningful contributor to Company revenue.”
“The science behind these wins is what makes them repeatable,” said Amar Sethi, MD, PhD, Chief Scientific Officer of VivoSim. “Our multi-endpoint profiling gives development teams in China the same translational signatures we deliver to partners in the U.S. and Europe — the ability to move from detecting liabilities to predicting risk, long before a single patient is dosed.”
Why This Matters for Investors
The company’s entry into mainland China expands its commercial footprint into a major pharmaceutical market and provides an opportunity to diversify its customer base beyond the U.S. and Europe. If the initial projects lead to repeat business, they could strengthen VivoSim’s position in the growing market for non-animal drug development tools.
The announcement also aligns with broader industry trends favoring New Approach Methodologies (NAMs). VivoSim noted increasing regulatory support for human-relevant testing, including the FDA’s efforts to reduce animal testing requirements for certain drug programs. Wider regulatory acceptance may support demand for platforms that can provide earlier insights into both drug safety and efficacy.
While the first Chinese contracts establish an important commercial milestone, future revenue growth will depend on converting these early customer relationships into recurring business and expanding adoption across additional pharmaceutical developers.
What to Watch Next
Investors will be looking for additional commercial contracts in China and the broader Asia-Pacific region, as well as updates on customer expansion through VivoSim’s distributor network.
Further attention will likely focus on growth in contracted revenue, continued adoption of the NAMkind™ platform, and regulatory developments that could accelerate the use of human tissue-based testing methods globally.